查詢結果分析
相關文獻
- 生物製劑於乾癬之治療應用
- 僵直性脊椎關節炎及乾癬性關節炎免疫生物製劑治療之新進展
- 新機轉中重度乾癬治療新藥Ustekinumab (Stelara®)
- 生物製劑治療期間定期監測結核病發生風險之必要性:臺灣專家之臨床經驗與建議
- The Taiwan Rheumatology Association Consensus Recommendations for Hepatitis B Virus Screening Contributes to Lower Mortality from Hepatitis B Reactivation in Rheumatic Patients: A Local Medical Center Study
- 免疫療法在非癌症皮膚疾病之應用
- 脫離“癬”境--淺談乾癬治療之生物製劑
- 尋常性乾癬合併類天疱瘡
- 乾癬皮膚病的臨床治療
- Langerhans Cell Histiocytosis in a Patient with Psoriasis
頁籤選單縮合
題名 | 生物製劑於乾癬之治療應用=Clinical Efficacy of Biologic Agents for Psoriasis Patients |
---|---|
作者 | 林佩姿; 林育昰; | 書刊名 | 藥學雜誌 |
卷期 | 35:2=139 2019.06[民108.06] |
頁次 | 頁37-43 |
分類號 | 418.33 |
關鍵詞 | 乾癬; 生物製劑; 抗腫瘤壞死因子抑制劑; 抗白細胞介素單株抗體; |
語文 | 中文(Chinese) |
中文摘要 | 乾癬為慢性全身發炎的免疫疾病,主要影響部位為皮膚,未妥善治療亦會影響到 其他器官。依據嚴重程度由輕至重度,可以選擇外用製劑或全身性藥物治療。生物製 劑則為近年來,中重度乾癬新興的全身性治療選擇之一,不會造成肝腎功能負擔,且 效果顯著。於一收納隨機臨床試驗的統合分析中顯示,ustekinumab 及 secukinumab 之 臨床治療效果,優於 adalimumab 和 etanercept。Infliximab 也有不錯成效,但目前台灣 僅核准於腸胃道相關免疫疾病之治療,陸續也有新型的生物製劑,相繼研發上市,相 信不久之後台灣病人也會有更多的治療選擇。 |
英文摘要 | Psoriasis is an inflammatory immune-mediated disease that affects the skin mainly. If poor disease control, it could induce other systemic diseases. Depended on severity of disease, it could be treated by topical to systemic medicine from mild to severe symptoms of psoriasis. Biological agents are one of new medicine for moderate to severe psoriasis recently and it does not affect renal and hepatic function and has significantly efficacy. As study results from a meta-analysis of randomized clinical trials, ustekinumab and secukinumab are better than adalimumab and etanercept for clinical treatment. Infliximab also could be used on psoriasis, but only approved for gastrointestinal immune-mediated disease in Taiwan. There are several new types of biological agents that have been successively launched. It is believed that patients in Taiwan will have more treatment options soon. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。